Kobashi-Margáin RA, Gavilanes-Espinar JG, Gutiérrez-Grobe Y, Gutiérrez-Jiménez ÁA, Chávez-Tapia N, Ponciano-Rodríguez G, Uribe M, Méndez SN

Language: English
References: 39
Page: 70-76
PDF size: 286.07 Kb.

ABSTRACT

Acute, acute-on-chronic and chronic liver diseases are major health issues worldwide, and most cases end with the need for liver transplantation. Up to 90% of the patients die waiting for an organ to be transplanted. Hepatic encephalopathy is a common neuropsychiatric syndrome that usually accompanies liver failure and impacts greatly on the quality of life. The molecular adsorbent recirculating system (MARS) is a recently developed form of artificial liver support that functions on a base of albumin dialysis. It facilitates the dialysis of albumin-bound and water-soluble toxins, allowing the patient to survive and even improving some clinical features of liver failure. The following manuscript reviews the technical features of MARS operation and some of the clinical trials that analyze the efficacy of the system in the therapy of liver diseases.

REFERENCES

1. Keeffe E. Hepatic failure and liver transplantation. In: Goldman. Cecil Medicine. Cap. 158. 23th. Ed. Saunders; 2007, p. 1147-52.

2. Sen S, Williams R, Jalan R. Emerging indications for albumin dialysis. Am J Gastroenterol 2005; 100: 468-75.

3. Pless G. Artificial and bioartificial liver support. Organogenesis 2007; 3(1): 20-4.

4. Stevens C. Liver Support Systems. Up to date 2008.

5. Stange J, Mitzner S, Ramlow W, Gliesche T, Hickstein H, Schmidt R. A new procedure for the removal of protein bound drugs and toxins. SAIO J 1993; 39: 621-5.

6. Mitzner ST, Stange J, Klammt S, et al. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 2001; 12: S75-S82.

7. Awad SS, Swaniker F, Bartlett RH. Results of a phase I trial evaluating a liver support device utilizing albumin dialysis. Surgery 2001; 130: 354-62.

8. Stange J, Mitzner S. A carrier-mediated transport of toxins in a Hybrid membrane. Safety barrier between a patient blood and bioartificial liver. Int J Artif Organs 1996; 19: 677-91.

9. Stange J, Ramlow W, Mitzner S, Schmidt R, Klinkmann H. Dyalisis against a recycled albumin solution enables the renoval of albumin-bound toxins. Artif Organs 1993; 17: 809-13.

10. Saliba F. The molecular adsorbent recirculating system (MARS) in the intensive care unit: a rescue therapy with hepatic failure. Critical Care 2006; 10(1): 186-9.

11. Sen S, Rose C, Ytrebø LM, et al. Effect of albumin dialysis on intracraneal pressure increase in pigs with acute liver failure: A randomized study. Critical Care Med 2006; 34: 158-64.

12. Sen S, Ytrebø LM, Rose C, et al. Albumin dialysis: a new therapeutic strategy for intoxication from protein bound drugs. Intensive Care Med 2004; 30: 496-501.

13. Sen S, Davies NA, Mookerjee RP, et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl 2004; 10: 1109-19.

14. Laleman W, Wilmer A, Evenepoel P, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2007; 10: 14.

15. Donati G, Piscaglia F, Coli L, Silvagni E, Righini R, Stefoni S, et al. Acute systemic, splachnic and renal hemodynamic changes Induced by molecular adsorbent recirculating system (MARS). Treatment in patients with end-stage cirrhosis. Aliment Pharmacol Ther 2007; 26: 717-26.

16. Parés A, Cisneros L, Salmerón JM, Caballería L, Mas A, Torras A, et al. Extracorporeal albumin dyalisis: A procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99: 1105-10.

17. Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: A prospective, controlled study. Hepatology 2002; 36: 949-58.

18. Mitzner SR, Klammt S, Peszynski P, Hickstein H, Korten G, Stange J, et al. Improvement of multiple organ functions in hepatorenal syndrome during albumin dyalisis with the molecular adsorbent recirculating system. Ther Apher 2001; 5: 417-22.

19. Camus C, Lavoué S, Gacouin A, et al. Molecular adsorbent recirculating system dialysis patients with acute liver failure who are assessed for liver transplantation. Intensive Care Med 2006; 32: 1817-25.

20. Wagholikar GD, Lee KH, Pandey D, et al. Pre-transplant optimization by molecular adsorbent recirculating system in patients with severely decompensated chronic liver disease. Indian J Gastroenterol 2007; 26: 110-2.

21. Choi JY, Bae SH, Yoon SK, et al. Preconditioning by extracorporeal liver support (MARS) of patients with cirrhosis and severe liver failure evaluated for living donor liver transplantation-a pilot study. Liver Int 2005; 25: 740-5.

22. Tan HK, Lim JS, Tan CK, et al. MARS therapy in critically ill patients with advanced malignancy: a clinical and technical report. Liver Int 2003; 23(Suppl. 3): 52-60.

23. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-onchronic liver failure a systematic review. JAMA 2003; 2: 217-22.

24. Lemoine M, Revaux A, Francoz C, et al. Albumin liver dialysis as pregnancy-saving procedure in cholestatic liver disease and intractable pruritus. World J Gastroenterol 2008; 14: 6572-4.

25. Wu BF, Wang MM. Molecular adsorbent recirculating system in dealing with maternal Amanita poisoning during the second pregnancy trimester: a case report. Hepatobiliary Pancreat Dis Int 2004; 3(1): 151-4.

26. Ilonen I, Koivusalo A, Repo H, Höckerstedt R, Isoniemi H. Cytokine profiles in acute liver failure treated with albumin dialysis. Artif Organs 2008; 32: 51-60.

27. Hassanein T, Oliver D, Stange J, Steiner C. Albumin dialysis in cirrhosis with superimposed liver injury: possible impact of albumin dialysis on hospitalization costs. Liver Int 2003; 23: 61-5.

28. Kantola T, Mäklin S, Koivusalo AM, et al. Cost-utility of molecular adsorbent recirculating system treatment in acute liver failure. World J Gastroenterol 2010; 16(18): 2227-34.

29. Jalan R, Williams R. Improvement in cerebral perfusion after MARS therapy: further clues about the pathogenesis of hepatic encephalopathy? Liver Transplantation 2001; 7(8): 713-5.

30. Seyan AS, Hughes RD, Shawcross DL. Changing face of hepatic encephalopathy: role of inflammation and oxidative stress. World J Gastroenterol 2010; 16(27): 3347-57.

31. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy- definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35(3): 716-21.

32. Schmidt LE, Svendsen LB, Sorensen VB, Hansen BA, Larsen FS. Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure. Liver Transplant 2001; 7(8): 709-12.

33. Mora JM, Olmedo R, Curiel E, et al. MARS (molecular adsorbent recirculating system) como asistencia extracorpórea hepática en el fracaso hepático agudo grave de etiología enólica. Med Intensiva 2006; 30(8): 402-6.

34. Hassanein TI, Tofteng F, Brown RS Jr, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007; 46: 1853-62.

35. Méndez-Sánchez N, Chávez-Tapia NC, Espinoza B, et al. Acute liver failure and the molecular adsorbents recirculating system: Early experience in a tertiary care hospital in Mexico City. Ann Hepatol 2004; 3(4): 164-6.

36. Schmidt LE, Svendsen LB, Sorensen VB, Hansen BA, Larsen FS. Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure. Liv Transplant 2001; 7(8): 709-12.

37. Mora JM, Olmedo R, Curiel E, et al. MARS (molecular adsorbent recirculating system) como asistencia extracorpórea hepática en el fracaso hepático agudo grave de etiología enólica. Med Intens 2006; 30(8): 402-6.

38. Hassanein TI, Tofteng F, Brown RS Jr, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007; 46: 1853-62.

39. Méndez-Sánchez N, Chávez-Tapia NC, Espinoza B, et al. Acute liver failure and the molecular adsorbents recirculating system: Early experience in a tertiary care hospital in Mexico City. Ann Hepatol 2004; 3(4): 164-6.